Search | Clinical Trials Finder

Conditions: Breast Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Interventions: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel; Drug · Other
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 782 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 1286
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 815 more

Conditions: Advanced Breast Cancer
Interventions: Camizestrant, Atirmociclib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: St Louis, Missouri • East Providence, Rhode Island • Nashville, Tennessee

Conditions: Breast Cancer
Interventions: trastuzumab (Herceptin®); Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Triple-negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer, NSCLC, Estrogen-receptor-positive Breast Cancer, Progesterone-receptor-positive Breast Cancer, Estrogen-receptor-negative Breast Cancer, ER-negative Breast Cancer, Progesterone-receptor Negative Breast Cancer, PR-negative Breast Cancer, HER2-negative Breast Cancer, ER-positive Breast Cancer, PR-positive Breast Cancer, Platinum-resistant Ovarian Cancer, Gastric Cancer, Pancreatic Cancer
Interventions: Zilovertamab vedotin; Drug
Lead sponsor: VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 8
States / cities: Hollywood, Florida • Orlando, Florida • Boston, Massachusetts + 5 more

Conditions: Hormone Receptor Positive Breast Cancer
Interventions: Everolimus, Letrozole, Exemestane, Alcohol-free dexamethasone mouth rinse (Stomatitis sub-study), Standard of care to treat stomatitis (Stomatitis sub-study); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 15
States / cities: Birmingham, Alabama • Gilbert, Arizona • Loma Linda, California + 12 more

Conditions: Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
Interventions: Palazestrant, Letrozole-matching placebo, Ribociclib, Letrozole, Palazestrant matching-placebo; Drug
Lead sponsor: Olema Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 62
States / cities: Hot Springs, Arkansas • Beverly Hills, California • La Jolla, California + 54 more

Conditions: Metastatic Breast Cancer
Interventions: Elacestrant; Drug
Lead sponsor: Stemline Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: Springdale, Arkansas • Chicago, Illinois • Las Vegas, Nevada + 1 more

Conditions: Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer
Interventions: Infigratinib, Tamoxifen, Omnipaque 350, Iopamidol, Computed tomography (CT); Drug · Diagnostic Test
Lead sponsor: Jennifer Lee Caswell-Jin; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Stanford, California

Conditions: Early Breast Cancer
Interventions: Giredestrant, Anastrozole, Palbociclib, Surgery; Drug · Procedure
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 10
States / cities: Burbank, California • Laguna Hills, California • San Luis Obispo, California + 7 more

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma
Interventions: DiviTum-TKa; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 18
States / cities: Derby, Connecticut • Fairfield, Connecticut • Glastonbury, Connecticut + 13 more

Conditions: Breast Cancer
Interventions: Taselisib, Placebo, Fulvestrant; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 631 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 16
States / cities: Tucson, Arizona • Atlanta, Georgia • Marietta, Georgia + 12 more

Conditions: Breast Cancer
Interventions: Ribociclib, letrozole; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 6
States / cities: Sedona, Arizona • Long Beach, California • Charlotte, North Carolina + 3 more

Conditions: Breast Cancer
Interventions: Ribociclib, Anastrozole, Letrozole, Goserelin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 14
States / cities: Mobile, Alabama • Greenbrae, California • Longmont, Colorado + 11 more

Conditions: Breast Cancer
Interventions: metformin hydrochloride, placebo; Drug · Other
Lead sponsor: Canadian Cancer Trials Group; Network
Eligibility: 18 Years to 74 Years
Enrollment: 3,649 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 280
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Scottsdale, Arizona + 213 more

Conditions: Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Interventions: Giredestrant, Fulvestrant, Abemaciclib, Palbociclib, Ribociclib, LHRH Agonist, FoundationOne Liquid CDx Assay (F1LCDx); Drug · Diagnostic Test
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,050 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 40
States / cities: Daphne, Alabama • Greenbrae, California • Harbor City, California + 34 more

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma
Interventions: Anastrozole, Biospecimen Collection, Bone Scan, Chemotherapy, Computed Tomography, Exemestane, Letrozole, Oncotype DX Breast Cancer Assay, Positron Emission Tomography, Ribociclib Succinate; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1,978 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 201
States / cities: Jonesboro, Arkansas • Auburn, California • Berkeley, California + 167 more

Conditions: ER+ HER2- Advanced Breast Cancer
Interventions: AZD9833, AZD9833 with palbociclib, AZD9833 with everolimus, AZD9833 with abemaciclib, AZD9833 with capivasertib, AZD9833 with ribociclib, AZD9833 with anastrozole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 5
States / cities: Aurora, Colorado • Sarasota, Florida • Philadelphia, Pennsylvania + 2 more

Conditions: Breast Cancer
Interventions: AC699; Drug
Lead sponsor: Accutar Biotechnology Inc; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 9
States / cities: Denver, Colorado • Orlando, Florida • Sarasota, Florida + 6 more

Conditions: Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, HER2/Neu Positive, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Interventions: Akt Inhibitor MK2206, Therapeutic Conventional Surgery, Pharmacological Study, Laboratory Biomarker Analysis; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: New York, New York • The Bronx, New York

Conditions: Breast Cancer
Interventions: Dato-DXd, Capecitabine, Gemcitabine, Eribulin, Vinorelbine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 732 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 14
States / cities: Duarte, California • Los Angeles, California • Palo Alto, California + 10 more

Conditions: Breast Cancer
Interventions: Pembrolizumab, RT Boost; Drug · Radiation
Lead sponsor: Stephen Shiao; Other
Eligibility: 18 Years and older · Female only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2030
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer, HER2-negative Breast Cancer, Node-negative Breast Cancer, Breast Carcinoma
Interventions: Anastrozole 1mg, Letrozole 2.5mg, Exemestane 25 mg, Tamoxifen; Drug
Lead sponsor: Irada Ibrahim-zada; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Invasive Breast Carcinoma, Localized Estrogen Receptor-Positive Breast Carcinoma, Localized Human Epidermal Growth Factor Receptor (HER2)-Negative Breast Carcinoma
Interventions: Abemaciclib, Biospecimen Collection, Imlunestrant, Questionnaire Administration, Radiologic Imaging Procedure; Drug · Procedure · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer
Interventions: PF-07248144, Fulvestrant, Everolimus, Exemestane; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 102
States / cities: Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 85 more

Search by objective public record fields.

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)

Tka Assay for CDK4/6i

A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy

A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Breast Cancer Study of Preoperative Pembrolizumab + Radiation

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.